Market Overview - The chemical pharmaceutical sector experienced a decline of 0.77% on January 20, with Kangzhi Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 4113.65, down 0.01%, while the Shenzhen Component Index closed at 14155.63, down 0.97% [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Hanshang Group (Code: 600774) with a closing price of 11.64, up 10.02% and a trading volume of 438,600 shares, totaling 489 million yuan [1] - Tainkang (Code: 301263) with a closing price of 32.71, up 7.04% and a trading volume of 138,300 shares, totaling 437 million yuan [1] - Sitaili (Code: 603520) with a closing price of 10.58, up 2.52% and a trading volume of 210,900 shares, totaling 225 million yuan [1] - Conversely, significant decliners included: - Kangyi Pharmaceutical (Code: 300086) with a closing price of 10.44, down 5.86% and a trading volume of 447,100 shares [2] - Dizhe Pharmaceutical (Code: 688192) with a closing price of 62.72, down 5.10% and a trading volume of 42,700 shares [2] - Guangji Pharmaceutical (Code: 000952) with a closing price of 7.52, down 4.93% and a trading volume of 292,200 shares [2] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 1.348 billion yuan from institutional investors, while retail investors contributed a net inflow of 1.109 billion yuan [2] - The capital flow for specific stocks indicated: - Huabang Health (Code: 002004) had a net inflow of 88.38 million yuan from institutional investors, but a net outflow of 73.07 million yuan from retail investors [3] - Fuxiang Pharmaceutical (Code: 300497) recorded a net inflow of 57.88 million yuan from institutional investors, with a net outflow of 102 million yuan from retail investors [3] - Xinqiao Pharmaceutical (Code: 000756) had a net inflow of 25.08 million yuan from institutional investors, but also saw a net outflow of 15.54 million yuan from retail investors [3]

齐鲁晚报.齐鲁壹点记者秦聪聪 一是守牢安全底线。我们坚持守底线保安全，以新安全格局保障新发展格局。不断完善地方属地、部门管理、企业主体"三位一体"责任落实体系，在全国 率先以党内文件出台药品安全党政同责规定，压实地方属地和部门管理责任。指导企业坚持"质量为本，以质取胜"，新华制药（000756）通过德国默克6 年的质量管理考核，签订年产值40亿元的跨国合作项目，成为全球医药合作"双向奔赴"的典范，也为全国药品企业主体责任落实树立了标杆。推动安全风 险防范关口前移，每季度开展全系统和各领域药品安全风险会商，加强常态化风险隐患排查治理。强化分级分类监管，扎实开展药品经营"清源"行动，针 对临床试验、委托生产、集采中选、网络销售等重点环节，强化靶向发力。药品抽检合格率达99.8%以上，高于全国平均水平。深化"罚帮并重"，在严格 处罚的同时，安排专人对违法企业进行帮扶，防范化解潜在风险，提升产品质量水平。 二是强化改革赋能。以改革促创新，积极对上争取支持，将山东纳入国家药监局药品和医疗器械审评检查京津冀分中心服务范围，成为唯一辐射京津冀之 外的省份，为强化京津冀鲁标准互认、监管协同打下坚实基础。获批全国首批优化药品补 ...

Group 1: Core Achievements in Innovation - Shandong state-owned enterprises have established a robust innovation ecosystem during the 14th Five-Year Plan, with 78 national-level research platforms and 609 provincial-level platforms, leading to 487 major scientific projects and 7 national science and technology awards [2] - The development of the "Intelligent Filling Green Mining Key Technology" by Shandong Gold has significantly reduced tailings storage by 2.33 million tons over three years, generating economic benefits exceeding 388 million yuan [3] - Shandong Energy Group has developed a complete set of intelligent and efficient mining technologies for deep coal resources, enhancing resource utilization and establishing a safety control system for deep mining [3] Group 2: Digital Transformation and AI Integration - Shandong enterprises are embracing digital transformation, with Inspur Group creating the first physical AI factory in China, integrating over 1,400 AI technology companies and forming 28 tightly coupled industrial clusters across various sectors [4] - The implementation of a digital foundation on the Jingtai Expressway has improved traffic efficiency by over 30% through innovative toll collection methods [4] - Shandong High-speed has developed an integrated intelligent perception system using AI technology, which has reduced average rescue times by over 6 minutes [5] Group 3: Collaborative Research in Pharmaceuticals - The establishment of the "Shandong Synthetic Biology and Green Intelligent Manufacturing Innovation Consortium" aims to address core technology challenges in the pharmaceutical industry, integrating 23 national and provincial research platforms [6] - The "Shandong Neurodegenerative Drug Research Innovation Consortium" has made significant progress in developing a multi-target small molecule drug for Alzheimer's disease, completing Phase I clinical trials with good safety results [7]

智通财经APP讯，山东新华制药股份(00719)发布公告，于2026年1月14日，该公司因2021年A股股票期 权激励计划首次授予合共690.69万股A股股份。 ...

山东新华制药（000756）股份(00719)发布公告，于2026年1月14日，该公司因2021年A股股票期权激励 计划首次授予合共690.69万股A股股份。 ...

Group 1 - The State Council Information Office will hold a press conference on January 14 to discuss the import and export situation for the entire year of 2025, with the Deputy Director of the General Administration of Customs, Wang Jun, presenting the information [1] - The Taiwan Affairs Office will also hold a press conference on January 14 to address recent cross-strait hot issues [2] Group 2 - On January 14, a total of 5 companies will have their restricted shares unlocked, with a total of 7.2278 million shares released, amounting to a market value of 151 million yuan at the latest closing price [3] - The companies with the highest number of unlocked shares are Xinhua Pharmaceutical, Huace Navigation, and Ruilian New Materials, with unlocked shares of 6.3748 million, 454,500, and 269,100 respectively [3] - The companies with the highest market value of unlocked shares are Xinhua Pharmaceutical (108 million yuan), Huace Navigation (1.84892 million yuan), and Ruilian New Materials (1.26923 million yuan) [3] Group 3 - On January 14, 14 companies disclosed their stock repurchase progress, with 4 companies announcing new repurchase plans, 2 companies reporting on the implementation of repurchase plans, and 8 companies completing their repurchase plans [4] - The highest repurchase plan amounts announced are from Kaifa Electric (up to 60 million yuan), Huazhi Jie (up to 50 million yuan), and Haojiang Intelligent (up to 3 million yuan) [4] - The companies with the highest repurchase amounts implemented are Huayuan Holdings (56.5399 million yuan) and Jichuan Pharmaceutical (2.6199 million yuan) [4] Group 4 - On January 14, 11 companies announced their progress on private placements, with 4 companies disclosing new private placement plans, 2 plans approved by shareholders, 4 plans approved by the CSRC, and 1 plan halted [5] - The companies with the highest proposed fundraising amounts are Shandong Yaobang (up to 3.235 billion yuan), Fulim Precision (up to 3.175 billion yuan), and Yuanwanggu (up to 691 million yuan) [5] Group 5 - Six A-shares will have their equity registration on January 14, with all six companies planning to distribute dividends [6] - The companies with the highest dividend payouts are Yunlu Co. (5.00 yuan per 10 shares), Fuan Energy (2.50 yuan per 10 shares), and Guangdong Mingzhu (2.00 yuan per 10 shares) [6]

Market Overview - US core CPI inflation slowdown failed to maintain stock market gains, with major indices turning negative; S&P 500 down 0.19%, Dow Jones down 0.80%, and Nasdaq down 0.10% [1] - Financial sector dragged down by bank stocks, with JPMorgan falling over 4% and Visa also down more than 4% after CFO hinted at potential impacts from credit card interest rate caps [1] - Google saw a rise of over 1%, marking four consecutive days of record highs, while AMD and Intel gained over 6% and 7% respectively after rating upgrades [1] Sector Performance - Nasdaq Golden Dragon China Index fell by 1.86%, with notable declines in Brain Rejuvenation Technology down over 26% and Pinduoduo down over 5% [2] - Offshore RMB initially rose post-US CPI release but later fell below 6.97, moving away from a 20-month high [4] Commodity Market - Oil prices rose for four consecutive days, reaching a two-month high, with a peak increase of over 3% following Trump's cancellation of talks with Iran [5] - Gold hit a record high before turning down, while silver rose nearly 5% in two days, achieving historical highs [5] Company Announcements - OpenAI's first hardware, reportedly AI headphones, aims for sales of 50 million units this year [6] - META plans to double the production capacity of AI glasses Ray-Ban to 20 million units by 2026, reflecting the rapid growth of the AI glasses market [7] - TCL Technology expects a net profit of 4.21 billion to 4.55 billion yuan for 2025, a year-on-year increase of 169% to 191% [19] - Dazhu CNC anticipates a net profit of 785 million to 885 million yuan for 2025, up 160.64% to 193.84% year-on-year [20] Industry Developments - The Ministry of Industry and Information Technology (MIIT) issued a plan to enhance the development of industrial internet platforms, aiming for over 120 million connected industrial devices by 2028 [8] - The MIIT held a meeting to implement a new round of growth stabilization plans for ten key industries, emphasizing the need to resist "involution" [9] - The Ministry of Commerce announced continued anti-dumping duties on solar-grade polysilicon from the US and South Korea for five years [10]

Core Viewpoint - On January 14, a total of 5 companies had their restricted shares unlocked, with a total unlock volume of 7.2278 million shares, amounting to a market value of 151 million yuan based on the latest closing price [1] Summary by Category Unlock Volume - The companies with the highest unlock volumes are Xinhua Pharmaceutical, Huace Navigation, and Ruile New Materials, with unlock shares of 6.3748 million, 454,500, and 269,100 respectively [1] Unlock Market Value - In terms of unlock market value, Xinhua Pharmaceutical, Huace Navigation, and Ruile New Materials lead with values of 10.8 million yuan, 1.84892 million yuan, and 1.26923 million yuan respectively [1] Unlock Ratio - Regarding the proportion of unlock shares to total share capital, Xinhua Pharmaceutical, Ruile New Materials, and Huace Navigation have the highest ratios, at 0.92%, 0.15%, and 0.06% respectively [1]

Core Viewpoint - On January 14, a total of 5 companies had their restricted shares unlocked, with a combined unlock volume of 7.2278 million shares, amounting to a market value of 151 million yuan based on the latest closing price [1] Summary by Category Unlock Volume - The companies with the highest unlock volumes were Xinhua Pharmaceutical, Huace Navigation, and Ruile New Materials, with unlock shares of 6.3748 million, 454,500, and 269,100 respectively [1] Unlock Market Value - In terms of unlock market value, Xinhua Pharmaceutical, Huace Navigation, and Ruile New Materials led with values of 10.8 million yuan, 1.84892 million yuan, and 1.26923 million yuan respectively [1] Unlock Ratio - Regarding the proportion of unlock shares to total share capital, Xinhua Pharmaceutical, Ruile New Materials, and Huace Navigation had the highest ratios at 0.92%, 0.15%, and 0.06% respectively [1]

证券代码：000756 证券简称：新华制药 公告编号：2026-01 山东新华制药股份有限公司 关于公司 2021 年 A 股股票期权激励计划首次授予 第三个行权期集中行权结果暨股份上市的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 特别提示： 1、本次行权的期权简称：新华 JLC2 2、本次行权的期权代码：037203 3、本次行权涉及人员 183 人，行权数量为 690.69 万份，占公司目前总股本的 1.00%。 4、本次行权采用集中行权模式。 5、本次行权股票上市流通时间为：2026 年 1 月 14 日。 2、2021 年 10 月 28 日，公司召开第十届监事会 2021 年第三次临时会议，审议通过了 《山东新华制药股份有限公司 2021 年 A 股股票期权激励计划（草案）》及其摘要的议案、 《山东新华制药股份有限公司 2021 年 A 股股票期权激励计划实施考核管理办法》的议案、 《关于核实<山东新华制药股份有限公司2021年A股股票期权激励计划首次授予激励对象名 单>》的议案。 3、2021 年 11 月 25 日，公司收到华鲁控股集团 ...